Q-omics provides the consensus-scored TPI1P4 profile across patient tissues and cancer cell-line models. TPI1P4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TPI1P4 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, TPI1P4 RNA expression shows 9,873 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, BLCA, and BRCA as cancer lineages where TPI1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPI1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPI1P4 survival associations across molecular data types. TPI1P4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPI1P4 RNA expression–survival associations across cancer types. High TPI1P4 expression shows unfavorable associations in LUAD, UVM, ACC, MESO, THCA and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TPI1P4 RNA expression.
This table summarizes TPI1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TPI1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPI1P4 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD, COAD, LUSC and KIRP. The BLCA box plot shows higher TPI1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.180, t-test p = .006).
This table shows molecular features associated with TPI1P4 in patient tissues and cancer cell lines. In patient samples, TPI1P4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
